

## Clinical features of spinal cord sarcoidosis: analysis of 17 neurosarcoidosis patients

Ken Sakushima · Ichiro Yabe · Fumihito Nakano ·  
Kazuto Yoshida · Yasutaka Tajima · Hideki Houzen ·  
Yasunori Maruo · Hidenao Sasaki

Received: 29 January 2011 / Accepted: 25 April 2011 / Published online: 7 May 2011  
© Springer-Verlag 2011

**Abstract** The diagnosis of neurosarcoidosis is often difficult; the imaging signs of spinal cord sarcoidosis sometimes mimic those of cervical spondylotic myelopathy, which is common in elderly persons. We examined the characteristics of spinal cord sarcoidosis in Japanese patients with neurosarcoidosis. This case series identified patients with neurosarcoidosis at four general hospitals and one university hospital from April 1998 to September 2010. All diagnoses were based on the diagnostic criteria proposed by Zajicek et al. Seventeen patients (nine men and eight women) were involved: six patients with spinal cord lesions accompanied by cervical spondylosis, five with cerebral lesions, three with cranial nerve lesions, two with meningitis, and one with nerve root lesions. Patients with spinal cord sarcoidosis had a higher onset age, longer duration from onset to diagnosis, reduced leukocytosis in the cerebrospinal fluid (CSF), and lower angiotensin-

converting enzyme (ACE) levels in the CSF. The results of this study indicate that diagnosis of spinal cord sarcoidosis requires careful evaluation.

**Keywords** Neurosarcoidosis · Spinal cord sarcoidosis · Cerebrospinal fluid · Angiotensin-converting enzyme

### Introduction

Neurosarcoidosis is a rare manifestation that occurs in 5% of systemic sarcoidosis patients; it is characterized by multisystem non-caseous granulomatous disease of an unknown etiology [1]. Neurosarcoidosis lesions mainly involve the optic and cranial nerves and the spinal cord [2]. The diagnosis of neurosarcoidosis is often difficult in clinical practice and requires magnetic resonance imaging (MRI) to detect the abnormalities and the evidence of systemic sarcoidosis [2, 3]. Spinal cord sarcoidosis exhibits intramedullary high-intensity signals on T2-weighted images (T2WI) and enhancements on gadolinium (Gd) DTPA-enhanced T1-weighted images (Gd-T1WI) [4, 5]; however, these signs also resemble cervical myelopathy with spondylosis [6]. Although cervical spondylotic myelopathy, which is common in elderly persons, sometimes mimics spinal cord sarcoidosis, a similar operative treatment is not effective for spinal cord sarcoidosis with cervical spondylosis [7]. Therefore, the diagnosis of spinal sarcoidosis is important for effective treatment. Systemic sarcoidosis shows racial differences in its incidence and clinical manifestations [8]. Case reports and case series on spinal cord sarcoidosis have been reported in western countries and Japan [5, 9]; however, the characteristics of spinal cord sarcoidosis have not been sufficiently investigated compared to other neurosarcoidosis lesions.

---


K. Sakushima (✉) · I. Yabe · H. Sasaki  
Department of Neurology, Hokkaido University Graduate  
School of Medicine, Sapporo, Japan  
e-mail: sakusima@med.hokudai.ac.jp

F. Nakano · K. Yoshida  
Department of Neurology, Asahikawa Red Cross Hospital,  
Asahikawa, Japan

Y. Tajima  
Department of Neurology, Sapporo City General Hospital,  
Sapporo, Japan

H. Houzen  
Department of Neurology, Obihiro Kosei General Hospital,  
Obihiro, Japan

Y. Maruo  
Department of Neurology, Hakodate Municipal Hospital,  
Hakodate, Japan



**Fig. 1** Distribution of laboratory findings at diagnosis for leukocytes in CSF (a), protein in CSF (b), glucose in CSF (c), and ACE in CSF (d). CSF cerebrospinal fluid, ACE angiotensin-converting enzyme

The purpose of this study was to identify the characteristics of spinal cord sarcoidosis that differentiate it from other neurosarcoidosis lesions in the Japanese population by reviewing consecutive patients in our hospital.

## Methods

This study enrolled patients diagnosed with neurosarcoidosis at the neurology departments of four general hospitals (Asahikawa Red Cross Hospital, Hakodate Municipal

Hospital, Sapporo Municipal Hospital, and Obihiro Kosei General Hospital) and one university hospital (Hokkaido University Hospital), from April 1998 to September 2010. The diagnosis of neurosarcoidosis was based on the diagnostic criteria proposed by Zajicek et al. [2] and the response to steroid treatment. We retrospectively reviewed medical records, and collected data on the course of neurosarcoidosis, diagnostic imaging, laboratory findings, and treatment regimens as well as their results. We compared patients with spinal cord sarcoidosis with patients with other forms of neurosarcoidosis. Age at onset, duration

**Table 1** Patient demographics

Case	Onset age <sup>a</sup> (years)	Sex	Duration <sup>b</sup> (months)	Neurological lesion	Systemic lesion	Serum ACE <sup>c</sup> (U/L)	Histology <sup>d</sup>	Diagnosis of neurosarcoidosis	Exacerbation during initial treatment	Comments
1	42	M	104	Spinal cord	M	24.4	M	Probable	Yes	MTX
2	61	F	6	Spinal cord	O, M	18.0	N.D.	Probable	No	MTX
3	61	M	27	Spinal cord	M	27.9	M	Probable	No	
4	76	F	24	Spinal cord	O, M	19.5	M	Probable	Yes	
5	63	F	6	Spinal cord	O, M, T	15.3	N.D.	Probable	Yes	
6	67	M	23	Spinal cord	O, M	23.0	M	Probable	No	
7	27	M	1	Cerebrum	O, A	23.9	A	Probable	No	MTX
8	26	M	51	Cerebrum	M	17.5	L	Probable	No	
9	28	M	1	Cerebrum	M	32.6	L	Probable	No	
10	25	M	7	Cerebrum	M	15.7	C	Definite	No	
11	33	M	1	Cerebrum	O	12.8	N.D.	Probable	No	
12	33	F	0	Cranial nerves	O, M, S	23.6	S	Probable	No	
13	57	F	3	Cranial nerves	M	14.4	M	Probable	No	
14	25	F	0	Cranial nerves	O, M, S	ND	S	Probable	No	
15	24	M	1	Meningitis	O, M	18.8	L	Probable	Yes	
16	70	F	13	Meningitis	O, S	15.0	S	Probable	No	
17	71	F	2	Nerve roots	M, S	33.6	L	Probable	No	

MTX Methotrexate was additionally administered during the initial corticosteroid treatment

M Mediastinal adenopathy, O Orbit, S Skin lesion, T Thyroid nodule, A Axillary adenopathy, L Lung, C Cerebrum, M male, F female, ND Not done


<sup>a</sup> Onset of neurological symptoms

<sup>b</sup> Duration between onset and diagnosis

<sup>c</sup> ACE Angiotensin-converting enzyme; Normal range 8.3–21.5 U/L

<sup>d</sup> The site of positive histology with sarcoidosis

**Fig. 2** Comparison of laboratory findings before and after treatment for serum angiotensin-converting enzyme (ACE) (a) and ACE in cerebrospinal fluid (CSF) (b). ACE angiotensin-converting enzyme



from the onset of neurological symptoms to the diagnosis of neurosarcoidosis, serum angiotensin-converting enzyme (ACE) levels, and cerebrospinal fluid (CSF) findings were compared using Mann–Whitney *U* test. We also compared laboratory findings before and after treatment to evaluate the usefulness of each item for disease activity. We excluded patients who did not have sufficient evidence of neurosarcoidosis, such as hemifacial palsy without abnormal

findings in diagnostic imaging. The Institutional Review Board of Hokkaido University Hospital approved this study.

**Results**

The demographics of the 17 patients are summarized in Table 1. Cases 3, 8, and 17 were previously described as

case reports by one of the authors of the present study [10–12]. There were six patients with spinal cord lesions, five with cerebral lesions, three with cranial nerve lesions, two with meningitis, and one with nerve root lesions. All spinal cord sarcoidoses occurred in the cervical cord, and they were accompanied by cervical spondylosis. Three of the spinal cord sarcoidosis patients underwent 2-[18F]-fluoro-2-deoxy-D-glucose positron emission tomography (FDG-PET) examinations [13], and all of them displayed abnormal uptake in the spinal cord lesion. Methotrexate was additionally administered during the initial corticosteroid treatment for cases 1, 2, and 7.

A comparison between patients with spinal cord sarcoidosis and those with other forms of neurosarcoidosis revealed significant differences in onset age, duration from onset to diagnosis, leukocytes in CSF, and ACE levels in CSF. The onset age in spinal cord sarcoidosis (mean  $\pm$  SD 61.0  $\pm$  10.5 years) was higher than in other forms of neurosarcoidosis (mean  $\pm$  SD 38.1  $\pm$  18.5 years). Duration from onset to diagnosis in spinal cord sarcoidosis (mean  $\pm$  SD 31.8  $\pm$  36.4 months) was longer than other neurosarcoidoses (mean  $\pm$  SD 7.3  $\pm$  15.0 months). Patients with spinal cord sarcoidosis had lower leukocyte and ACE levels in CSF than patients with other forms of neurosarcoidosis (Fig. 1).

Alterations in the ACE levels after treatment for neurosarcoidosis are shown in Fig. 2. Serum ACE levels decreased in spinal cord sarcoidosis and other forms of neurosarcoidosis after treatment with corticosteroids. The reduction in ACE levels in CSF was less obvious than that in serum.

## Discussion

We identified some characteristics of spinal cord sarcoidosis from our case series. First, spinal cord sarcoidosis tended to occur in elderly patients and required a longer duration to develop from onset to diagnosis. Second, leukocytes and ACE levels were not elevated in CSF of spinal cord sarcoidosis patients. Third, serum ACE levels reflected the disease activity after treatment.

A national survey on sarcoidosis in Japan revealed the incidence rate to be 1.01 per 100,000 individuals, with 7.2% of these cases displaying neurological complications [14]. The incidence rate exhibited a bimodal distribution that consisted of young men and middle-aged to elderly women. In our cases, spinal cord sarcoidosis was mainly associated with the elderly. Conversely, cerebral lesions in neurosarcoidosis were mainly associated with younger men. A longer duration between onset and diagnosis in spinal cord sarcoidosis may be associated with the elderly patients and cervical spondylosis complications, because cervical myelopathy mimicked the clinical symptoms of spinal cord sarcoidosis. Laboratory findings are essential

for the diagnosis of neurosarcoidosis; however, spinal cord sarcoidosis resulted in less frequent abnormal findings in CSF than other forms of neurosarcoidosis in our study. Varron et al. [5] reported that four of seven cases of spinal cord sarcoidosis had normal or near-normal cell counts, and six of them had normal ACE levels in CSF. Cohen-Aubart et al. [15] also reported that eight of 28 cases of spinal cord sarcoidosis had normal cell counts and more than 50% patients had normal ACE levels in CSF. These characteristics indicate that careful evaluation for spinal cord sarcoidosis is required for patients with systemic sarcoidosis and cervical spondylosis.

2-[18F]-fluoro-2-deoxy-D-glucose positron emission tomography is becoming an additional diagnostic tool for different forms of neurosarcoidosis, including spinal cord sarcoidosis [9, 16]. We recently reported the usefulness of FDG-PET for the differentiation of spinal cord sarcoidosis from cervical spondylotic myelopathy [13].

Spinal cord sarcoidosis is one of the steroid-refractory lesions among neurosarcoidoses and often requires additional immunosuppressant therapy [17]. Methotrexate may be useful to maintain optimal disease suppression [3]. Therefore, indicators that represent the disease activity of spinal cord sarcoidosis are necessary for reasonable treatment. Oksanen et al. [18] reported the usefulness of ACE levels in CSF measured by an inhibitor binding assay to evaluate the disease activity of neurosarcoidosis; however, colorimetry was used in the present case, while investigation by Varron et al. [5] demonstrated that spinal cord sarcoidosis patients did not exhibit sufficient changes in the CSF-ACE levels to serve as an indicator. Although the methods used to measure ACE levels were different in each study, the symptoms caused by spinal cord lesions are still reliable indicators of spinal cord sarcoidosis. At the very least, on the basis of our findings, we propose that serum ACE levels may reflect the disease activity of neurosarcoidosis as a part of systemic sarcoidosis.

In conclusion, a review of Japanese patients with neurosarcoidosis found that spinal cord sarcoidosis is frequent in elderly patients with neurosarcoidosis and evinces fewer CSF abnormalities than other forms of neurosarcoidosis.

**Conflict of interest** None.

## References

1. Baughman RP, Teirstein AS, Judson MA, Rossman MD, Yeager H Jr, Bresnitz EA, DePalo L, Hunninghake G, Iannuzzi MC, Johns CJ, McLennan G, Moller DR, Newman LS, Rabin DL, Rose C, Rybicki B, Weinberger SE, Terrin ML, Knatterud GL, Cherniak R (2001) Clinical characteristics of patients in a case control study of sarcoidosis. *Am J Respir Crit Care Med* 164:1885–1889
2. Zajicek JP, Scolding NJ, Foster O, Rovaris M, Evanson J, Moseley IF, Scadding JW, Thompson EJ, Chamoun V, Miller

- DH, McDonald WI, Mitchell D (1999) Central nervous system sarcoidosis—diagnosis and management. *QJM* 92:103–117
3. Joseph FG, Scolding NJ (2007) Sarcoidosis of the nervous system. *Pract Neurol* 7:234–244
  4. Saleh S, Saw C, Marzouk K, Sharma O (2006) Sarcoidosis of the spinal cord: literature review and report of eight cases. *J Natl Med Assoc* 98:965–976
  5. Varron L, Broussolle C, Candessanche JP, Marignier R, Rousset H, Ninet J, Seve P (2009) Spinal cord sarcoidosis: report of seven cases. *Eur J Neurol* 16:289–296
  6. Ozawa H, Sato T, Hyodo H, Ishii Y, Morozumi N, Koizumi Y, Matsumoto F, Kasama F, Aizawa T, Itoi E, Kokubun S (2009) Clinical significance of intramedullary Gd-DTPA enhancement in cervical myelopathy. *Spinal Cord* 48:415–422
  7. Oe K, Doita M, Miyamoto H, Kanda F, Kurosaka M, Sumi M (2009) Is extensive cervical laminoplasty an effective treatment for spinal cord sarcoidosis combined with cervical spondylosis? *Eur Spine J* 18:570–576
  8. Rybicki BA, Major M, Popovich J Jr, Maliarik MJ, Iannuzzi MC (1997) Racial differences in sarcoidosis incidence: a 5-year study in a health maintenance organization. *Am J Epidemiol* 145:234–241
  9. Ota K, Tsunemi T, Saito K, Yamanami F, Watanabe M, Irioka T, Mizusawa H (2009) (18)F-FDG PET successfully detects spinal cord sarcoidosis. *J Neurol* 256(11):1943–1946
  10. Takahashi I, Soma H, Sakushima K, Tsuji-Akimoto S, Niino M, Yabe I, Sasaki H (2010) Cervical intramedullary sarcoidosis diagnosed after laminoplasty for spondylosis. *Shinkei Chiryogaku (Neurological Therapeutics)* 27:209–213
  11. Matsushima M, Miyazaki Y, Kano T, Tsuji S, Sasaki H (2006) Central nervous system sarcoidosis with extensive cerebral edema. *ShinkeiNaika (Neurological Medicine)* 64:314–316
  12. Sakushima K, Niino M, Yabe I, Akimoto-Tsuji S, Sasaki H (2009) Weakness and sensory disturbance of the left extremities. *J Clin Neurosci* 16:1608–1711
  13. Sakushima K, Yabe I, Shiga T, Yashima-Yamada M, Tsuji-Akimoto S, Terae S, Sasaki H (2011) FDG-PET SUV can distinguish between spinal sarcoidosis and myelopathy with canal stenosis. *J Neurol* 258:227–230
  14. Morimoto T, Azuma A, Abe S, Usuki J, Kudoh S, Sugisaki K, Oritsu M, Nukiwa T (2008) Epidemiology of sarcoidosis in Japan. *Eur Respir J* 31:372–379
  15. Cohen-Aubart F, Galanaud D, Grabli D, Haroche J, Amoura Z, Chapelon-Abrieu C, Lyon-Caen O, Valeyre D, Piette JC (2010) Spinal cord sarcoidosis: clinical and laboratory profile and outcome of 31 patients in a case-control study. *Medicine (Baltimore)* 89:133–140
  16. Braun JJ, Kessler R, Constantinesco A, Imperiale A (2008) 18F-FDG PET/CT in sarcoidosis management: review and report of 20 cases. *Eur J Nucl Med Mol Imaging* 35:1537–1543
  17. Bradley DA, Lower EE, Baughman RP (2006) Diagnosis and management of spinal cord sarcoidosis. *Sarcoidosis Vasc Diffuse Lung Dis* 23:58–65
  18. Oksanen V, Fyhrquist F, Somer H, Gronhagen-Riska C (1985) Angiotensin converting enzyme in cerebrospinal fluid: a new assay. *Neurology* 35:1220–1223